Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I pharmacokinetic and safety study of SCD-044 in healthy adults
jRCT2071240027Phase 1Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vibozilimod in psoriasis and atopic dermatitis (AD) (3 cohorts), sponsored by Sun Pharma. Primary endpoints: AUC0-inf of SCD-044 and Cmax of SCD-044. Started Jul 2024; status: active, not recruiting.
02
Drugs
vibozilimod
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2071240027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240027.